The AAIC 2026 primary-care findings show an Alzheimer's blood test — a plasma measure of amyloid-beta 42/40 and phosphorylated-tau 217 — lifted primary-care diagnostic accuracy from 65% to 93%, near dementia specialists' 94%. For memory-clinic patients, the test was strongest for ruling out Alzheimer's, with remaining limits around confirmation, kidney function, and use outside specialty care. The evidence comes from a Swedish real-world study led by Lund University's Sebastian Palmqvist in 1,310 patients with mild impairment or dementia and 165 physicians. The Alzheimer's Association reported the results July 14, 2026 at AAIC 2026 in London, as interim findings from 383 primary-care and 927 specialty-care patients.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How accurate was the test in primary care?
- How did results change diagnoses and next steps?
- Where are the evidence gaps for U.S. memory clinics?
- What should patients and families do now?
How accurate was the test in primary care?
Primary-care doctors started at 65% diagnostic accuracy before seeing blood-test results. After disclosure, accuracy reached 93%, nearly matching specialists' 94%, as Clinical Lab Products reported in its July 15 summary. The study used C2N's PrecivityAD2 test, which measures amyloid-beta 42/40 plus percent phosphorylated-tau 217 in plasma.
That combination reflects core Alzheimer's pathology in blood rather than symptoms alone. The Alzheimer's Association reported the test was strongest for ruling out Alzheimer's disease in primary care rather than ruling it in alone, in its AAIC release. A negative result therefore carries more weight than a positive result standing by itself.
How did results change diagnoses and next steps?
After disclosure, physicians changed the diagnosis in about one-third of patients. They also changed future care or testing plans in over half of patients. That matters because an early label guides referrals, safety planning, work decisions, and family support.
A corrected diagnosis can redirect a patient away from Alzheimer's treatment toward vascular, sleep, mood, thyroid, or medication-related causes, or the reverse. For memory-clinic patients, the practical point is triage. A primary-care blood result can sharpen the referral question and reduce unneeded specialty workups, but it does not replace full specialty evaluation.
Where are the evidence gaps for U.S. memory clinics?
These are interim results from Swedish primary-care and specialty-care patients. That design limits direct generalization to diverse U.S. memory-clinic populations with different ages, coexisting diseases, and referral patterns. U.S.
rules also keep blood biomarkers in a defined role. FDA-cleared tests, starting with Fujirebio Lumipulse on May 16, 2025 for symptomatic adults 55 and older, are aids only for symptomatic evaluation, not healthy-person screening, according to the FDA clearance announcement. Alzheimer's Association 2025 guidance limits routine blood-biomarker use to specialty evaluation of cognitive impairment. It requires confirmatory spinal-fluid testing or amyloid-PET after a lower-specificity positive triage result before diagnosis is fixed.
What should patients and families do now?
Chronic kidney disease can falsely raise p-tau blood results. Memory-clinic patients with low kidney function need cautious reading of results and often confirmatory testing, according to National Geographic reporting on Mayo Clinic neurology guidance. Useful steps for a cognitive concern visit include: Bring recent kidney lab results when available, because the doctor will need them to interpret p-tau.
- Seek prompt primary care for persistent memory, thinking, or daily-function changes.
- Bring symptom examples, medications, sleep history, and known kidney problems.
- Ask whether a blood result rules out Alzheimer's or needs spinal-fluid or PET confirmation.
- Expect specialty referral when symptoms persist, results conflict, or treatment decisions depend on certainty.
You Might Also Like
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: How Memory Clinic Patients Can Compare Testing Options
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Access, Cost, and Follow-Up Questions for Memory Clinic Patients
- How 2026 Tau Imaging News May Affect Alzheimer’s Workups: Access, Cost, and Follow-Up Questions for Memory Clinic Patients
